 "Wockhardt Q4 results: Drug maker's net loss shrinks to Rs 45 crore")
Drug firm Wockhardt on Thursday reported a consolidated net loss of Rs 45 crore in the fourth quarter ended March 31, 2025.
The drug maker had reported a net loss of Rs 177 crore in the January-March quarter of FY24.
Revenue from operations rose to Rs 743 crore in the fourth quarter as compared to Rs 700 crore in the year-ago period, Wockhardt said in a regulatory filing.
For FY25, the company said its net loss stood at Rs 57 crore as compared to Rs 472 crore in the year-ago period.
Revenue increased to Rs 3,012 crore as compared to Rs 2,798 crore in 2023-24 fiscal.
Shares of the company closed at Rs 1,347.75 apiece, 0.63 per cent higher from previous close, on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app